COZAAR Drug Patent Profile
✉ Email this page to a colleague
When do Cozaar patents expire, and what generic alternatives are available?
Cozaar is a drug marketed by Organon and is included in one NDA.
The generic ingredient in COZAAR is losartan potassium. There are thirty-nine drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the losartan potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cozaar
A generic version of COZAAR was approved as losartan potassium by ALEMBIC PHARMS LTD on October 6th, 2010.
Summary for COZAAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 187 |
| Clinical Trials: | 77 |
| Patent Applications: | 4,384 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for COZAAR |
| What excipients (inactive ingredients) are in COZAAR? | COZAAR excipients list |
| DailyMed Link: | COZAAR at DailyMed |
Recent Clinical Trials for COZAAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Actuate Therapeutics | Phase 2 |
| Colin D. Weekes, M.D. | Phase 2 |
| Lustgarten Foundation | Phase 2 |
Pharmacology for COZAAR
| Drug Class | Angiotensin 2 Receptor Blocker |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for COZAAR
US Patents and Regulatory Information for COZAAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-001 | Apr 14, 1995 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-002 | Apr 14, 1995 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-003 | Oct 13, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COZAAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-003 | Oct 13, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-001 | Apr 14, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-003 | Oct 13, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-001 | Apr 14, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-001 | Apr 14, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-003 | Oct 13, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Organon | COZAAR | losartan potassium | TABLET;ORAL | 020386-001 | Apr 14, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COZAAR
See the table below for patents covering COZAAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 85312 | PROCESSO PARA A PREPARACAO DE IMIDAZOIS BLOQUEADORES DOS RECEPTORES DE ANGIOTENSINA II E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM | ⤷ Try a Trial |
| Denmark | 359687 | ⤷ Try a Trial | |
| Spain | 2063734 | ⤷ Try a Trial | |
| Ireland | 960772 | ⤷ Try a Trial | |
| Germany | 69123582 | ⤷ Try a Trial | |
| Israel | 88900 | ⤷ Try a Trial | |
| Finland | 99012 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COZAAR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0733366 | SZ 25/1998 | Austria | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN-KALIUM UND HYDROCHLOROTHIAZID |
| 0733366 | 98C0030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: KALII LOSARTAN, HYDROCHLOROTHIAZIDUM; NAT. REGISTRATION NO/DATE: 922 IS 174 F 3 19980223; FIRST REGISTRATION: FR 338 520.7 19950215 |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 0253310 | C950009 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 17617 19950314; FIRST REGISTRATION: SE 12209 19940902 |
| 0253310 | SZ 16/1996 | Austria | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN-KALIUM |
| 0480717 | 98C0025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
